围产期胸腹盆腔肿瘤的产前诊断与出生后管理:多中心经验
这项回顾性多中心研究纳入2010年1月至2021年5月法兰西岛地区产前或出生后3个月内诊断的153例胸腹盆腔肿瘤患儿。仅35%(53/153)产前检出,出生后检出者远处转移比例更高(36% vs 4%),中位随访5年时89%存活,作者认为提高早期检出有助于出生后多学科管理和家长指导。
要点
- 153例围产期胸腹盆腔肿瘤中仅35%(53/153)产前检出,主要发现于孕晚期(62%)。
- 产前检出者远处转移4%(2/53),出生后检出者为36%(36/100)。
- 中位随访5年时136例(89%)存活。
核心结论
- 仅35%的围产期胸腹盆腔肿瘤在出生前检出,虽以恶性为主但预后总体良好。
- 作者认为改善早期检出可能有助于出生后多学科管理和家长指导。
研究设计与样本
- 回顾性多中心研究,纳入2010年1月至2021年5月法兰西岛地区产前或出生后3个月内诊断的胸腹盆腔肿瘤患儿,共153例。
- 从病历中提取产前影像检出肿块的孕周或出生后首次出现肿瘤相关症状的日龄,以及出生后诊断确认(临床影像学或病理)的时间。
主要发现
- 153例肿瘤中,14例(9%)合并先天畸形,4例(3%)有已知种系致病性变异。
- 肿瘤主要部位为肾上腺(43%)、肾上腺外及肾外腹膜后(12%)和肾脏(12%)。
- 最常见诊断为神经母细胞瘤93/153(61%)(包括肾上腺65例、肾上腺外腹膜后20例、胸部/纵隔8例)、肝母细胞瘤10/153(7%)、畸胎瘤10/153(7%)、肾母细胞瘤8/153(5%)和先天性中胚层肾瘤7/153(5%)。
- 35%(53/153)产前检出肿块(主要于孕晚期62%),出生后中位9天(IQR 2-20天)确认诊断;65%(100/153)出生后检出,主要依据肿瘤肿块综合征(39%)或家长/常规体检触及肿块(36%),出生后中位73天(IQR 39-104天)检出。
- 产前检出者远处转移4%(2/53),出生后检出者36%(36/100);5例因压迫性肿瘤行医疗性终止妊娠,另1例宫内胎死;5例(3%)新生儿因呼吸窘迫、动脉性高血压、肠穿孔或肠梗阻需早期支持性重症监护;中位随访5年(范围0-14年)时136例(89%)存活。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The primary objective was to assess the accuracy of prenatal examination in detecting and characterizing perinatal solid tumors of the thoracoabdominopelvic region. Secondary objectives were to describe the epidemiology, clinical characteristics and outcome of these tumors. METHODS: This was a retrospective multicenter study of all patients with a thoracic, abdominal or pelvic tumor diagnosed prenatally or within the first 3 months after birth in the Île-de-France area between January 2010 and May 2021. The gestational age at which a mass was detected on prenatal imaging, or the postnatal age at which the first tumor-related sign or symptom was noted, in addition to the timing of postnatal diagnostic confirmation (clinicoradiological or pathological), were extracted from patient medical files. RESULTS: Overall, 153 tumors were identified. An associated congenital malformation was identified in 14 (9%) infants and four (3%) had a known germline pathogenic variant. The main tumor locations were adrenal gland (43%), extra-adrenal and extrarenal retroperitoneum (12%) and kidney (12%). The most common diagnoses were neuroblastoma (93/153 (61%)) (including 65 adrenal, 20 extra-adrenal retroperitoneal and eight thoracic/mediastinal), hepatoblastoma (10/153 (7%)), teratoma (10/153 (7%)), nephroblastoma (8/153 (5%)) and congenital mesoblastic nephroma (7/153 (5%)). In 35% (53/153) of cases, a mass was detected prenatally (mainly during the third trimester (62%)) and the diagnosis was confirmed at a median of 9 (interquartile range (IQR), 2-20) days after birth. Tumor detection was postnatal in 65% (100/153) of cases, mainly on the basis of tumor mass syndrome (39%) or tumor palpation by parents or during a routine medical visit (36%), and occurred at a median of 73 (IQR, 39-104) days after birth. Distant metastasis was noted in 4% (2/53) of cases with a prenatal mass and in 36% (36/100) of cases detected postnatally. Five medical terminations of pregnancy for a compressive tumor were reported, in addition to one in-utero fetal demise. Five (3%) neonates required early supportive intensive care due to respiratory distress, arterial hypertension, intestinal perforation or intestinal obstruction. At a median follow-up of 5 (range, 0-14) years, 136 (89%) patients remained alive. CONCLUSIONS: Only 35% of perinatal thoracic, abdominal and pelvic tumors were detected before birth. Although mainly malignant, their prognosis was largely favorable. Improving early detection may assist postnatal multidisciplinary management and parental guidance. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Khawand C, Orbach D, Berrebi D, et al. Prenatal diagnosis and postnatal management of perinatal thoracoabdominopelvic tumors: multicenter experience. Ultrasound Obstet Gynecol. 2025. PMID: 40847681. doi:10.1002/uog.70000
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。